IEHP UM Subcommittee Approved Authorization Guideline

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Reference Product Pegfilgrastim and Biosimilar Products</th>
<th>Guideline #</th>
<th>UM_OTH 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section</td>
<td>Other</td>
<td>Original Effective Date</td>
<td>11/13/2019</td>
</tr>
</tbody>
</table>

**COVERAGE POLICY**

**A. Neulasta (pegfilgrastim)**
Requests may be approved if all of the following criteria are met:
1. Treatment with **Fulphila** (pegfilgrastim-jmdb) and **Udenyca** (pegfilgrastim-cbqv) has been ineffective, not tolerated, or both are contraindicated; and
2. Requested dosage is consistent with FDA approved labeling

**B. Neulasta Onpro (pegfilgrastim autoinjector device)**
Requests may be approved if all of the following criteria are met:
1. Documentation that patient is not able to return to provider office (due to significant behavioral issues, physical difficulties or cognitive impairment) for administration of **Fulphila** (pegfilgrastim-jmdb) or **Udenyca** (pegfilgrastim-cbqv); and
2. Milliman Care Guidelines (MCG) criteria for Granulocyte Colony-Stimulating Factor (G-CSF) are met; and
3. Requested dosage is consistent with FDA approved labeling

**C. Fulphila (pegfilgrastim-jmdb)**
Requests may be approved if all of the following criteria are met:
1. Pegfilgrastim-jmdb is reimbursable when used to reduce the incidence of neutropenia-related infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
2. Requested dosage is consistent with FDA approved labeling

**D. Udenyca (pegfilgrastim-cbqv)**
Requests may be approved if all of the following criteria are met:
1. Milliman Care Guidelines (MCG) for Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) A-0314 is met
2. Requested dosage is consistent with FDA approved labeling

**E. Continued Therapy**
Re-authorization may be reviewed every 6 months. Clinical documentation (including, but not limited to chart notes) must be provided to confirm that current medical necessity criteria are met.
COVERAGE LIMITATIONS AND EXCLUSIONS
Request for investigational indications that lack established clinical benefits and safety are not covered.

ADDITIONAL INFORMATION
The Biological Price Competition and Innovation Act passed in 2009 established the pathway for approval of biosimilars with the goal of reducing expenditure for costly biologic drug. A biosimilar is a biological product that demonstrates high similarity to the FDA-approved originator (reference) product by extensive comparative analysis of the products, such as purity, chemical identity and bioactivity. The FDA may approve biosimilars for the same indications as the originator product when human pharmacokinetic and pharmacodynamic studies also demonstrated no clinically meaningful differences from the reference product in terms of safety, purity and potency.

In 2018, the U.S. Food and Drug Administration (FDA) approved the first pegfilgrastim biosimilars, pegfilgrastim-jmdb (Fulphila) and pegfilgrastim-cbqv (Udenyca), for the same indications as their reference product pegfilgrastim (Neulasta). They are the long-acting granulocyte-colony stimulating factors (G-CSFs) that help reduce the risk of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

Applicable Codes
The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement policy.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2505</td>
<td>Injection, pegfilgrastim, 6mg</td>
</tr>
<tr>
<td>Q5108</td>
<td>Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5mg</td>
</tr>
<tr>
<td>Q5111</td>
<td>Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5mg</td>
</tr>
</tbody>
</table>

CLINICAL/REGULATORY RESOURCE
B. Department of Health Care Services Medi-Cal Provider Manual:
   1. Pegfilgrastim-jmdb is reimbursable when used to reduce the incidence of neutropenia-related infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

C. Milliman Care Guidelines (MCG) 22nd Edition 2019:
   1. Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) may be indicated for 1 or more of the following:
      a. Acute myeloid leukemia and 1 or more of the following:
         i. Induction chemotherapy using filgrastim
         ii. Induction chemotherapy using sargramostim and ALL of the following:
• Age 55 years or older
• Less than 10% blasts in bone marrow or blood

iii. Consolidation chemotherapy using filgrastim
iv. Salvage chemotherapy following relapse

b. Acute radiation exposure and 1 or more of the following:
   i. Absolute neutrophil count less than 500/mm³ (0.5 x10⁹/L) and expected to persist for 1 week or more
   ii. Lymphocyte count less than 1400/mm³ (1.4 x10⁹/L) at 48 hours
   iii. Radiation dose (confirmed or suspected) of greater than 2 Gy

c. Myelodysplastic syndrome and ALL of the following:
   i. Absolute neutrophil count less than 1500/mm³ (1.5 x10⁹/L)
   ii. History of recurrent or resistant infections

d. Myeloid engraftment for hematopoietic stem cell transplant and 1 or more of the following
   i. Hematopoietic stem cell transplant failure or delay in engraftment
   ii. Mobilization of peripheral blood progenitor cell prior to stem cell transplant
   iii. Nonmyeloid malignancy undergoing myeloablative chemotherapy followed by bone marrow or peripheral blood progenitor cell transplant

e. Myelosuppressive chemotherapy for nonmyeloid malignancy (first cycle) and 1 or more of the following
   i. Administration of 3 or more myelosuppressive agents
   ii. Age 65 years or older
   iii. Chemotherapy regimen has historical risk of febrile neutropenia of greater than 20%
   iv. Elevated alkaline phosphatase
   v. Elevated bilirubin
   vi. Elevated lactate dehydrogenase
   vii. Glomerular filtration rate less than 30 mL/min/1.73m² (0.50 mL/sec/1.73m²)
   viii. HIV infection with low CD4 counts
   ix. Low serum albumin
   x. Low serum hemoglobin
   xi. Pre-existing bone marrow involvement with tumor
   xii. Pre-existing infection
   xiii. Pre-existing neutropenia
   xiv. Pre-existing open wound
   xv. Previous chemotherapy
   xvi. Previous radiation therapy
   xvii. Recent surgery

f. Myelosuppressive chemotherapy for nonmyeloid malignancy (subsequent cycle) and ALL of the following:
   i. Chemotherapy dose delay or reduction is not desirable
   ii. History of neutropenia, as indicated by 1 or more of the following:
      • Febrile neutropenia with prior chemotherapy cycle
      • Prolonged neutropenia with prior chemotherapy cycle
g. Severe chronic neutropenia, as indicated by 1 or more of the following:
   i. Diagnosis of congenital neutropenia confirmed
   ii. Diagnosis of cyclic neutropenia confirmed
   iii. Diagnosis of idiopathic neutropenia confirmed

D. **National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium 2019:**

<table>
<thead>
<tr>
<th>NCCN Recommended Use</th>
<th>Neulasta (pegfilgrastim)</th>
<th>Fulphila (pegfilgrastim-jmdb)</th>
<th>Udenyca (pegfilgrastim-cbqv)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment for patients who present with acute exposure to myelosuppressive doses of RT</td>
<td>2A</td>
<td>2A</td>
<td>2A</td>
</tr>
<tr>
<td>Prophylaxis of chemotherapy-induced febrile neutropenia or other dose-limiting neutropenic events in intermediate-risk (10% to 20% overall risk of febrile neutropenia) patients with solid tumors and nonmyeloid malignancies receiving treatment in the curative/adjuvant or palliative settings who have one or more patient risk factors</td>
<td>2A</td>
<td>2A</td>
<td>2A</td>
</tr>
<tr>
<td>Prophylaxis of chemotherapy-induced febrile neutropenia or other dose-limiting neutropenic events in high-risk (&gt;20% overall risk of febrile neutropenia) patients with solid tumors and nonmyeloid malignancies receiving treatment in the curative/adjuvant or palliative settings</td>
<td>1</td>
<td>2A</td>
<td>2A</td>
</tr>
<tr>
<td>Used for supportive care post autologous hematopoietic cell transplant</td>
<td>2A</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

E. **National Comprehensive Cancer Network (NCCN) Hematopoietic Growth Factor Clinical Practice Guidelines 2019:**

1. In 2018, the FDA approved the first pegfilgrastim biosimilars, pegfilgrastim-jmdb and pegfilgrastim-cbqv, for the same indications as their reference products. The FDA’s approval of these biosimilars was based on review of evidence including structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data.

2. Pegfilgrastim-jmdb
   a. Pegfilgrastim-jmdb has been shown to have high analytical and functional similarity to pegfilgrastim, with similar structure, molecular mass, physiochemical characteristics, impurities and G-CSF receptor binding affinity. A phase I randomized equivalence trial concluded that pegfilgrastim-jmdb demonstrated similar pharmacokinetics, pharmacodynamics and safety to pegfilgrastim in healthy volunteers.
   b. In a multicenter randomized phase III efficacy and safety trial, breast cancer patients receiving myelosuppressive chemotherapy with pegfilgrastim-jmdb
support showed no difference in the duration of severe neutropenia, time to ANC nadir, duration of post-nadir recovery, or treatment-related adverse events compared to patients receiving reference pegfilgrastim.

3. Pegfilgrastim-cbqv
   a. Although data are limited, pegfilgrastim-cbqv was shown to have a similar safety profile and bioequivalent pharmacokinetics and pharmacodynamics to pegfilgrastim in 122 healthy volunteers in a multicenter randomized crossover study. No serious treatment-related adverse events were observed with the use of pegfilgrastim-cbqv.

DEFINITION OF TERMS
1. Biosimilar – A biological product that is highly similar to the FDA-approved originator (reference) product with the exception of minor differences in clinically inactive components and no differences in efficacy, safety and purity⁴.

REFERENCES

DISCLAIMER
IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.